Vedani Sébastien Michel, Petitprez Séverine, Weinz Eva, Corpataux Jean-Marc, Déglise Sébastien, Deslarzes-Dubuis Céline, Côté Elisabeth, Ricco Jean-Baptiste, Saucy François
Department of Vascular Surgery, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland.
Department of Clinical Research, University of Poitiers, 86073 Poitiers, France.
J Clin Med. 2022 Jun 6;11(11):3232. doi: 10.3390/jcm11113232.
Aneurysm shrinkage has been proposed as a marker of successful endovascular aneurysm repair (EVAR). We evaluated the impact of sac shrinkage on secondary interventions, on survival and its association with endoleaks, and on compliance with instructions for use (IFU). This observational retrospective study was conducted on all consecutive patients receiving EVAR for an infrarenal abdominal aortic aneurysm (AAA) using exclusively Endurant II/IIs endograft from 2014 to 2018. Sixty patients were entered in the study. Aneurysm sac shrinkage was defined as decrease ≥5 mm of the maximum aortic diameter. Univariate methods and Kaplan-Meier plots assessed the potential impact of shrinkage. Twenty-six patients (43.3%) experienced shrinkage at one year, and thirty-four (56.7%) had no shrinkage. Shrinkage was not significantly associated with any demographics or morbidity, except hypertension ( = 0.01). No aneurysm characteristics were associated with shrinkage. Non-compliance with instructions for use (IFU) in 13 patients (21.6%) was not associated with shrinkage. Three years after EVAR, freedom from secondary intervention was 85 ± 2% for the entire series, 92.3 ± 5.0% for the shrinkage group and 83.3 ± 9% for the no-shrinkage group (Logrank: = 0.49). Survival at 3 years was not significantly different between the two groups (85.9 ± 7.0% vs. 79.0 ± 9.0%, Logrank; = 0.59). Strict compliance with IFU was associated with less reinterventions at 3 years (92.1 ± 5.9% vs. 73.8 ± 15%, Logrank: = 0.03). Similarly, survival at 3 years did not significantly differ between strict compliance with IFU and non-compliance (81.8 ± 7.0% vs. 78.6 ± 13.0%, Logrank; = 0.32). : This study suggests that shrinkage ≥5 mm at 1-year is not significantly associated with a better survival rate or a lower risk of secondary intervention than no-shrinkage. In this series, the risk of secondary intervention regardless of shrinkage seems to be linked more to non-compliance with IFU. Considering the small number of patients, these results must be confirmed by extensive prospective studies.
动脉瘤缩小已被提议作为血管内动脉瘤修复术(EVAR)成功的一个标志。我们评估了瘤腔缩小对二次干预、生存率的影响,及其与内漏的关联,还有与使用说明(IFU)依从性的关系。这项观察性回顾性研究针对2014年至2018年期间所有连续接受EVAR治疗肾下腹主动脉瘤(AAA)且仅使用Endurant II/IIs血管内支架的患者。60名患者纳入研究。动脉瘤瘤腔缩小定义为主动脉最大直径减少≥5毫米。单变量方法和Kaplan-Meier曲线评估了缩小的潜在影响。26名患者(43.3%)在1年时出现缩小,34名(56.7%)未出现缩小。除高血压外(P = 0.01),缩小与任何人口统计学特征或发病率均无显著关联。没有动脉瘤特征与缩小相关。13名患者(21.6%)未遵守使用说明与缩小无关。EVAR术后3年,整个系列免于二次干预的比例为85±2%,缩小组为92.3±5.0%,未缩小组为83.3±9%(对数秩检验:P = 0.49)。两组3年生存率无显著差异(85.9±7.0%对79.0±9.0%,对数秩检验;P = 0.59)。严格遵守使用说明与3年时较少的再次干预相关(92.1±5.9%对73.8±15%,对数秩检验:P = 0.03)。同样,严格遵守使用说明和未遵守使用说明的患者3年生存率无显著差异(81.8±7.0%对78.6±13.0%,对数秩检验;P = 0.32)。结论:本研究表明,1年时缩小≥5毫米与无缩小相比,在生存率或二次干预风险方面无显著更好的关联。在本系列中,无论是否缩小,二次干预的风险似乎更多地与未遵守使用说明有关。鉴于患者数量较少,这些结果必须通过广泛的前瞻性研究加以证实。